DOCSLIB.ORG

Brenner Tumour of the Vagina

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brenner Tumour of the Vagina 67868 Clin Pathol 1995;48:678-679 Brenner tumour of the vagina A-M H Rashid, H Fox J Clin Pathol: first published as 10.1136/jcp.48.7.678 on 1 July 1995. Downloaded from Abstract The Brenner tumour was first described by Polyps ofthe vagina are rare and are either Fritz Brenner in 1907,' who postulated that it Departent of of inflammatory/reactive or neoplastic was derived from the granulosa cells of the Pathology, Western origin. A case of extraovarian Brenner ovarian follicles. Apart from a few cases pre- Memorial Hospital, a senting outside the ovary, Brenner tumours are P.O. Box 2005, tumour ofthe vagina in postmenopausal Corner Brook, woman, who presented with a vaginal almost exclusively ovarian.2 Here, we report Newfoundland polyp, is described. The polyp was excised such a tumour arising in a vaginal polyp. A2H 6J7, Canada and on histological examination, had the A-M H Rashid triphasic pattern (transitional, glandular Department of and stromal) characteristic of Brenner Case report Pathology, University tumour. The histogenesis of Brenner A 77 year old diabetic white woman presented of Manchester, Manchester tumour is discussed in the context of this with a few months history of vaginal irritation H Fox unusual location and the controversy ofits and soreness. On pelvic examination, there was origin. a polyp, 2 cm in diameter, arising from the Correspondence to: Dr A-M H Rashid. (J7 Clin Pathol 1995;48:678-679) vaginal vault. No bleeding or signs of infection Accepted for publication were noted. A simple polypectomy under local 1 December 1994 Keywords: Brenner tumour, vagina, histogenesis. anaesthesia was carried out. Past medical history revealed that the patient had had a hysterectomy with bilateral salpingo- oophorectomy for dysfunctional uterine bleed- ing 20 years before. PATHOLOGY The excised specimen consisted of a smooth surfaced polyp measuring 2 x 1-8 cm at max- imum diameter. On sectioning, the cut surface was grey-yellow in colour and had small cystic areas. Microscopically, the polyp was covered by a slightly thickened vaginal mucosa. Em- http://jcp.bmj.com/ bedded in the fibrocellular connective tissue core were numerous rounded solid islands and nests of uniform cells showing clear cytoplasm and oval shaped, grooved, nuclei reminiscent of transitional type epithelium (fig 1). Some of these islands had central lumina with a pink acellular secretion, whereas within others, oc- on September 29, 2021 by guest. Protected copyright. casional small glandular structures lined by Figure 1 Nests of epithelial cells located within the connective tissue stroma. simple columnar cells were noted (fig 2). The (Haematoxylin and eosin; original magnification x 200.) triphasic (transitional, glandular and stromal) appearance of this polyp is characteristic of Brenner tumour. On review of the previous total hysterectomy specimen, there was no evidence of an ovarian Brenner tumour. The patient was followed for 18 months with no recurrence. Discussion Neoplasms of the vagina are uncommon. Both benign and malignant tumours are composed of pure or mixed epithelial or stromal elements."4 Most vaginal polyps are benign tumours of connective tissue origin-for example, fibroma, leiomyoma, nerve sheath tumours, haem- angioma, and rhabdomyoma. Of the non- neoplastic polypoid lesions, fibroepithelial and inflammatory granulation polyps are the most common. Figure 2 Gland-like structures within the transitional epithelium. (Haematoxylin and Extraovarian Brenner tumours are extremely eosin; original magnification x 400.) rare. To date, they have been reported in the Brenner tumour of the vagina 679 broad ligament,5-7 the uterus,8 the vagina,9 and ovarian coelomic epithelium via a process of the testicular and para-testicular tissues.'0`2 wolffian differentiation has been supported by For a diagnosis of Brenner tumour, both in- serial reconstruction studies, by its coexistence tegral components (the epithelial and me- with other ovarian tumours, and by ultra- senchymal stroma) must be present.278 structural studies.'3 Remnants of the wolffian J Clin Pathol: first published as 10.1136/jcp.48.7.678 on 1 July 1995. Downloaded from There is only one documented case of ex- ductal system are known to occur in the broad traovarian Brenner tumour of the vagina in the ligament, cervix and vagina, and must be ser- literature.9 A similar case, however, has been iously regarded as an alternative source of the reported by Buntine et al3 who called the polyp neoplasm in an extraovarian site.2 This theory "benign mixed mullerian tumour ofthe vagina" is supported by fact that the tumour is biphasic and pointed out its resemblance to Brenner and that it resembles the transitional epithelium tumour. Shevchuk et al,4 in their case of "malig- lining the genitourinary tract. nant mixed tumour of the vagina", were prob- A Brenner tumour of the vagina could there- ably describing a malignant Brenner tumour. fore be derived directly from wolffian remnants The authors commented that the ultra- at this site or could originate from mullerian structural findings of their case confirmed ductal tissue which forms the upper part of the urothelial differentiation and that the tumour vagina, by a process of wolffian metaplasia. appeared to arise from mesonephric remnants. 1 Brenner F. Ds oophoroma folliculare. Frank Zeitschr Path It seems that the reason for the confusion in 1907;1: 150-7 1. the nomenclature of this neoplasm is because 2 Pschera H, Wikstrom B. Extraovarian tumor coexisting with serous cystadenoma. Gynecol Obstet Invest 1991 ;31: 185-7. of its bi- or triphasic nature. 3 Buntine DW, Henderson PR, Biggs JSG. Benign mullerian The histogenesis of Brenner tumour is still mixed tumor of the vagina. Gynecol Oncol 1979;8:21-6. 4 Shevchuk MM, Fenoglio CM, Lattes R, Frick HC, Richart controversial.2613 The important proposed sites RM. Malignant mixed tumor ofthe vagina probably arising of origin include ovarian surface epithelium6'3; in mesonephric rests. Cancer 1978;42:214-23. 5 Robinson TG. Extraovarian Brenner tumor. Obstet Gynecol remnants of embryonic coelomic epithe- 1950;57:890-1. lium248; displaced mesothelium69 12; rests of 6 Hampton HL, Huffman HT, Meeks RG. Extraovarian Bren- ner tumour. Obstet Gynecol 1992;79:844-6. Waltbard's cells612 13; and remnants of mull- 7 Wagner I, BettendorfU. Extraovarian Brenner tumour. Case erian,29-12 mesonephric,27 1 13 or wolffian report and review. Arch Gynecol 1980;229:191-6. 8 Arhelger RB, Bocian JJ. Brenner tumor ofthe uterus. Cancer ducts.49 1011 13 Other less likely possible sources 1976;38:1741-3. are as follows: ovarian stroma2 8 13; rete 9 Chen KTK. Brenner tumor of the vagina. Diagn Gynecol 1 Obstet 1981;3:255-8. ovarii2 13; rete testis 2; germ cell (teratomatous) 10 Goldman RL. A Brenner tumor of the testis. Cancer 1970; derivation7 12 13; granulosa cells'; ectopic (ac- 26:853-6. 11 Ross L. Paratesticular Brenner-like tumor. Cancer 1968;21: cessory) ovarian tissue8; ovotestis'2; and ves- 722-6. tibular glands of the vagina.9 12 Young RH, Scully RE. Testicular and paratesticular tumors and tumor-like lesions of ovarian common epithelial and The presence of the tumour in men and at mullerian types. A report of four cases and review of the sites far away from the ovary indicates that this literature. Am J Clin Pathol 1986;86:146-52. 13 Balasa RW, Adcock LL, Prem KA, Dehner LP. The Brenner neoplasm is not invariably of ovarian origin. tumor: a clinicopathological review. Obstet Gynecol 1976; The concept of this neoplasm originating from 50:120-8. http://jcp.bmj.com/ I Clin Pathol 1995;48:679-681 Departent of on September 29, 2021 by guest. Protected copyright. Haematology, St Luc Hospital, Catholic University of Louvain, Brussels, Belgium P-glycoprotein positive, drug resistant invasive J L Gala J Rodhain lymphoepithelial thymoma: treatment response A Ferrant Department of to chemotherapy with cyclosporin and quinine Pathology H Noel Department of Haematology, Queen J L Gala, H Noel, J Rodhain, D F F Ma, A Ferrant Astrid Military Hospital, Brussels, Belgium J L Gala Abstract therapy without resolution of the tumour. Department of A case ofinvasive drug resistant thymoma, More than 90% ofthe malignant epithelial Haematology, Royal were for North Shore Hospital, expressing P-glycoprotein, which showed cells strongly positive P-gly- Sydney, Australia noticeable clinical response to chemo- coprotein and based on this observation, D FF Ma therapy and the multidrug resistance cyclosporin and quinine were added to the Correspondence to: modulating agents cyclosporin and quin- chemotherapy regimen. The mediastinal Dr J L Gala, Department of ine is reported. A 46 year old man pre- mass completely resolved and the size of Haematology, Laboratory of Clinical Molecular Biology, sented with severe left shoulder pain and the pleural metastasis decreased sub- Cliniques Universitaires St a diagnosis of invasive lymphoepithelial stantially. The patient, however, died of Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium. thymoma was made following chest x ray an intercurrent infection. This case report Accepted for publication and a computed tomography scan. The highlights the feasibility and efficacy of 26 September 1994 patient underwent extensive chemo- using cyclosporin and quinine in com-.
Load more

Recommended publications
  • Histological Tumour Type (Required)
    Histological tumour type (Required) Reason/Evidentiary Support All ovarian epithelial malignancies and borderline tumours should be typed according to the WHO classification.1 There are 5 major subtypes of primary ovarian carcinoma, high‐grade serous, clear cell, endometrioid, mucinous and low‐ grade serous.2‐5 There are also other uncommon minor subtypes, those listed by the WHO including malignant Brenner tumour, seromucinous carcinoma and undifferentiated carcinoma.1 Carcinosarcoma is a mixed epithelial and mesenchymal malignancy but is included in the category of epithelial malignancies in this dataset since most are of epithelial origin and histogenesis.6 Although management of ovarian carcinoma is, at present, largely dependent on tumour stage and grade, accurate typing will almost certainly become more important in the future with the introduction of targeted therapies and specific treatments for different tumour types. This is in part because, although clinically often considered as one disease, there is an increasing realisation that the different morphological subtypes of ovarian carcinoma have a different pathogenesis, are associated with distinct molecular alterations and have a different natural history, response to traditional chemotherapy and prognosis.2‐5 Tumour typing may also be important in identifying or initiating testing for an underlying genetic predisposition; for example, high‐grade serous carcinoma may be associated with underlying BRCA1/2 mutation while endometrioid and clear cell carcinomas can occur in patients with Lynch syndrome.7 The most common ovarian carcinoma is high‐grade serous carcinoma (approximately 70%) followed by clear cell and endometrioid.8,9 Mucinous and low‐grade serous are less common. Approximately 90% of advanced stage ovarian carcinomas (stage III/IV) are high‐grade serous in type.8,9 Most primary tubal carcinomas are high‐grade serous or endometrioid and most primary peritoneal carcinomas are of high‐grade serous type.
    [Show full text]
  • Pleomorphic Adenoma of Buccal Mucosa: a Rare Case Report
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 16, Issue 3 Ver. XI (March. 2017), PP 75-78 www.iosrjournals.org Pleomorphic Adenoma of Buccal Mucosa: A Rare Case Report Ashwini Jangamashetti, BDS1, Siddesh Shenoy, MDS2, R.Krishna Kumar MDS3, Amol Jeur, MS4 1Post Graduate Student, Department Of Oral Medicine And Radiology, MARDC,Pune 2Reader, Department of oral Medicine and radiology, M.A Rangoonwala Dental College and Research Center, Pune (MARDC), 3Professor and HOD, Department of oral Medicine and Radiology, MARDC, Pune 4Assistant Professor in Department of General surgery, Krishna Medical College of KIMS Deemed University , Abstract: Pleomorphic adenoma is a benign tumor of the salivary gland that consists of a combination of epithelial and mesenchymal elements1. About 90% of these tumors occur in the parotid gland and 10% in the minor salivary glands2. Among intra oral pleomorphic adenomas buccal vestibule is among the rarest sites3. A case of pleomorphic adenoma of minor salivary glands in the buccal vestibule in a 36 year-old female is discussed4. It includes review of literature, clinical features, histopathology, radiological findings and treatment of the tumor, with emphasis on diagnosis4. The mass was removed by wide local excision with adequate margins5. Keywords: minor salivary gland, pleomorphic adenoma, tumor, parotid gland, vestibule, mesenchymal elements. I. Introduction Pleomorphic adenoma (PA) is defined by World Health Organization in 1972 as a circumscribed tumor characterized by its pleomorphic or mixed appearance clearly recognizable epithelial tissue being intermingled with tissue of mucoid, myxoid and chondroid appearance2. Among all salivary gland tumors, pleomorphic adenoma is the most frequently encountered lesion accounting for approximately 60% of all salivary gland neoplasms3.
    [Show full text]
  • Soft Tissue Cytopathology: a Practical Approach Liron Pantanowitz, MD
    4/1/2020 Soft Tissue Cytopathology: A Practical Approach Liron Pantanowitz, MD Department of Pathology University of Pittsburgh Medical Center [email protected] What does the clinician want to know? • Is the lesion of mesenchymal origin or not? • Is it begin or malignant? • If it is malignant: – Is it a small round cell tumor & if so what type? – Is this soft tissue neoplasm of low or high‐grade? Practical diagnostic categories used in soft tissue cytopathology 1 4/1/2020 Practical approach to interpret FNA of soft tissue lesions involves: 1. Predominant cell type present 2. Background pattern recognition Cell Type Stroma • Lipomatous • Myxoid • Spindle cells • Other • Giant cells • Round cells • Epithelioid • Pleomorphic Lipomatous Spindle cell Small round cell Fibrolipoma Leiomyosarcoma Ewing sarcoma Myxoid Epithelioid Pleomorphic Myxoid sarcoma Clear cell sarcoma Pleomorphic sarcoma 2 4/1/2020 CASE #1 • 45yr Man • Thigh mass (fatty) • CNB with TP (DQ stain) DQ Mag 20x ALT –Floret cells 3 4/1/2020 Adipocytic Lesions • Lipoma ‐ most common soft tissue neoplasm • Liposarcoma ‐ most common adult soft tissue sarcoma • Benign features: – Large, univacuolated adipocytes of uniform size – Small, bland nuclei without atypia • Malignant features: – Lipoblasts, pleomorphic giant cells or round cells – Vascular myxoid stroma • Pitfalls: Lipophages & pseudo‐lipoblasts • Fat easily destroyed (oil globules) & lost with preparation Lipoma & Variants . Angiolipoma (prominent vessels) . Myolipoma (smooth muscle) . Angiomyolipoma (vessels + smooth muscle) . Myelolipoma (hematopoietic elements) . Chondroid lipoma (chondromyxoid matrix) . Spindle cell lipoma (CD34+ spindle cells) . Pleomorphic lipoma . Intramuscular lipoma Lipoma 4 4/1/2020 Angiolipoma Myelolipoma Lipoblasts • Typically multivacuolated • Can be monovacuolated • Hyperchromatic nuclei • Irregular (scalloped) nuclei • Nucleoli not typically seen 5 4/1/2020 WD liposarcoma Layfield et al.
    [Show full text]
  • BSOG-FOGSI Quiz Preliminary Round Conducted on 24Th April at API
    BSOG-FOGSI quiz preliminary round conducted on 24th April at API Bhavana South Zone Yuva Fogsi 2016 Quiz – BSOG round Topic- Gynecological Oncology 24th April, 2016 (60 marks) Name: Institution: Dear participants, Welcome to the FOGSI Quiz 2016 Thirty questions are to be answered in 30 minutes. Circle the right answer. Scratching and overwriting will get a negative marking even if the final answer is right. Each correct answer gets 2 marks and a wrong one gets a negative marking of minus 1.The top 2 scorers will represent BSOG in South Zone Yuva FOGSI 2016 in Madurai on 22nd May 2016. The decision of the Quiz Master is final. Happy Quizzing!!! 1. With regards to the staging of endometrial cancer, pick the wrong answer a. Stage 1a Endometrial Adenocarcinoma is confined to the uterus and involves less than half of the myometrium b. Stage 4a Endometrial Adenocarcinoma invades bladder mucosa c. Stage 4b Endometrial Adenocarcinoma involves inguinal lymph nodes d. Stage 3c2 Endometrial Adenocarcinoma involves more than half of myometrium and pelvic lymph nodes Ans: Stage 3c1 is involvement of pelvic nodes, Stage 3c2 is involvement of paraaortic nodes 2. The average time between HPV infection and pre-cancer is a. 2-5 years b. 15-20 years c. 7-10 years d. 20-25 years Novak 3. What factor does not contribute to persistence and progression of HPV infection? a. Smoking b. Contraceptive use c. STDs d. Drinking alcohol Novak 4. On Colposcopy, Adenocarcinoma has the following features a. Mosaic pattern b. Punctate lesions c. Abnormal vasculature d.
    [Show full text]
  • Mesenchymal) Tissues E
    Bull. Org. mond. San 11974,) 50, 101-110 Bull. Wid Hith Org.j VIII. Tumours of the soft (mesenchymal) tissues E. WEISS 1 This is a classification oftumours offibrous tissue, fat, muscle, blood and lymph vessels, and mast cells, irrespective of the region of the body in which they arise. Tumours offibrous tissue are divided into fibroma, fibrosarcoma (including " canine haemangiopericytoma "), other sarcomas, equine sarcoid, and various tumour-like lesions. The histological appearance of the tamours is described and illustrated with photographs. For the purpose of this classification " soft tis- autonomic nervous system, the paraganglionic struc- sues" are defined as including all nonepithelial tures, and the mesothelial and synovial tissues. extraskeletal tissues of the body with the exception of This classification was developed together with the haematopoietic and lymphoid tissues, the glia, that of the skin (Part VII, page 79), and in describing the neuroectodermal tissues of the peripheral and some of the tumours reference is made to the skin. HISTOLOGICAL CLASSIFICATION AND NOMENCLATURE OF TUMOURS OF THE SOFT (MESENCHYMAL) TISSUES I. TUMOURS OF FIBROUS TISSUE C. RHABDOMYOMA A. FIBROMA D. RHABDOMYOSARCOMA 1. Fibroma durum IV. TUMOURS OF BLOOD AND 2. Fibroma molle LYMPH VESSELS 3. Myxoma (myxofibroma) A. CAVERNOUS HAEMANGIOMA B. FIBROSARCOMA B. MALIGNANT HAEMANGIOENDOTHELIOMA (ANGIO- 1. Fibrosarcoma SARCOMA) 2. " Canine haemangiopericytoma" C. GLOMUS TUMOUR C. OTHER SARCOMAS D. LYMPHANGIOMA D. EQUINE SARCOID E. LYMPHANGIOSARCOMA (MALIGNANT LYMPH- E. TUMOUR-LIKE LESIONS ANGIOMA) 1. Cutaneous fibrous polyp F. TUMOUR-LIKE LESIONS 2. Keloid and hyperplastic scar V. MESENCHYMAL TUMOURS OF 3. Calcinosis circumscripta PERIPHERAL NERVES II. TUMOURS OF FAT TISSUE VI.
    [Show full text]
  • The Role of Cytogenetics and Molecular Diagnostics in the Diagnosis of Soft-Tissue Tumors Julia a Bridge
    Modern Pathology (2014) 27, S80–S97 S80 & 2014 USCAP, Inc All rights reserved 0893-3952/14 $32.00 The role of cytogenetics and molecular diagnostics in the diagnosis of soft-tissue tumors Julia A Bridge Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA Soft-tissue sarcomas are rare, comprising o1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with 4100 benign and malignant soft-tissue tumor entities defined. Not infrequently, these neoplasms exhibit overlapping clinicopathologic features posing significant challenges in rendering a definitive diagnosis and optimal therapy. Advances in cytogenetic and molecular science have led to the discovery of genetic events in soft- tissue tumors that have not only enriched our understanding of the underlying biology of these neoplasms but have also proven to be powerful diagnostic adjuncts and/or indicators of molecular targeted therapy. In particular, many soft-tissue tumors are characterized by recurrent chromosomal rearrangements that produce specific gene fusions. For pathologists, identification of these fusions as well as other characteristic mutational alterations aids in precise subclassification. This review will address known recurrent or tumor-specific genetic events in soft-tissue tumors and discuss the molecular approaches commonly used in clinical practice to identify them. Emphasis is placed on the role of molecular pathology in the management of soft-tissue tumors. Familiarity with these genetic events
    [Show full text]
  • SNOMED CT Codes for Gynaecological Neoplasms
    SNOMED CT codes for gynaecological neoplasms Authors: Brian Rous1 and Naveena Singh2 1Cambridge University Hospitals NHS Trust and 2Barts Health NHS Trusts Background (summarised from NHS Digital): • SNOMED CT is a structured clinical vocabulary for use in an electronic health record. It forms an integral part of the electronic care record, and serves to represent care information in a clear, consistent, and comprehensive manner. • The move to a single terminology, SNOMED CT, for the direct management of care of an individual, across all care settings in England, is recommended by the National Information Board (NIB), in “Personalised Health and Care 2020: A Framework for Action”. • SNOMED CT is owned, managed and licensed by SNOMED International. NHS Digital is the UK Member's National Release Centre for the creation of, and delegated authority to licence the SNOMED CT Edition and derivatives. • The benefits of using SNOMED CT in electronic care records are that it: • enables sharing of vital information consistently within and across health and care settings • allows comprehensive coverage and greater depth of details and content for all clinical specialities and professionals • includes diagnosis and procedures, symptoms, family history, allergies, assessment tools, observations, devices • supports clinical decision making • facilitates analysis to support clinical audit and research • reduces risk of misinterpretations of the record in different care settings • Implementation plans for England: • SNOMED CT must be implemented across primary care and deployed to GP practices in a phased approach from April 2018. • Secondary care, acute care, mental health, community systems, dentistry and other systems used in direct patient care must use SNOMED CT as the clinical terminology, before 1 April 2020.
    [Show full text]
  • Brenner Tumor with Serous Cystadenoma- an Unusual Combination: a Case Report
    DOI: 10.5958/2319-5886.2015.00045.4 International Journal of Medical Research & Health Sciences www.ijmrhs.com Volume 4 Issue 1 Coden: IJMRHS Copyright @2014 ISSN: 2319-5886 Received: 6th Nov 2014 Revised: 28th Nov 2014 Accepted: 31st Dec 2014 Case report BRENNER TUMOR WITH SEROUS CYSTADENOMA- AN UNUSUAL COMBINATION: A CASE REPORT *Syam Sundar B1, Shanthi V1, Mohan Rao N1, Bhavana Grandhi2, Chidananda Reddy V 2, Swathi S2 1Associate Professor, 2Assistant professor, Department of Pathology, Narayana Medical College, Nellore, A.P, India *Corresponding author email: syam.byna&gmail.com ABSTRACT Surface epithelial tumors are most common, which comprise 58% of all ovarian tumors. Serous and mucinous cystadenoma are the most common epithelial tumors which accounts for about 35% of ovarian tumors. Different combinations of epithelial tumors can occur in ovary most common among them is Mucinous cystadenoma and Brenner tumor. We report a case of an ovarian tumor with rare combination Brenner tumor with serous cyst adenoma of ovary in 56 year old female patient. Only a few cases with this combination are very rarely reported in the literature. Keywords: Brenner Tumor, Serous cystadenoma. INTRODUCTION Surface epithelial tumors are the most important CASE REPORT group of neoplasm of ovary which are namely serous, mucinous, endometroid, clear cell and Brenner along A 56 year old female patient presented with a with combinations of these types1. Surface epithelial swelling in the lower abdomen with intermittent tumors occur at all ages with a peak incidence in 2nd abdominal pain over a period of 1 year. Clinically, to 5th decade of life.
    [Show full text]
  • Cutaneous Fetal Rhabdomyoma a Case Report and Historical Review of the Literature
    CASE REPORT Cutaneous Fetal Rhabdomyoma A Case Report and Historical Review of the Literature Sarah N. Walsh, MD* and Mark A. Hurt, MDw mas; such articles have documented different histologic Abstract: Fetal rhabdomyomas are well-documented tumors, types, local regrowth and possible malignancy, a broader affecting both children and adults that are composed of age distribution, various immunohistochemical staining immature striated muscle at the sixth to tenth-week stage of patterns, occurrence in particular syndromes, and their development. Although there is often a predilection for the head presence in a wide assortment of organs and anatomic and neck region, these tumors have been identified in a wide sites.1,2,4–8,11,15,16,18,20–25,29,33 To the best of our knowl- array of anatomic sites. A primary cutaneous presentation, edge, however, fetal rhabdomyoma has never been however, has not yet been described. We report the first case of a diagnosed definitively in the skin. We present the first fetal rhabdomyoma arising in the skin of a 1-year old girl. After case of a cutaneous fetal rhabdomyoma found in a 1- the initial biopsy, an incomplete excision was performed with year-old girl with a lesion on the chin. tumor present histologically at multiple surgical margins. In a follow-up period of 54 months, there has been no lesional regrowth or evidence of further progression. This case is CASE REPORT detailed, in addition to a literature-based review of the historical The patient was a 1-year-old girl seen by a pediatric and conceptual development of the neoplasm known as fetal dermatologist for a chin lesion that had been present for the past 10 months but had not changed noticeably during that period.
    [Show full text]
  • Rotana Alsaggaf, MS
    Neoplasms and Factors Associated with Their Development in Patients Diagnosed with Myotonic Dystrophy Type I Item Type dissertation Authors Alsaggaf, Rotana Publication Date 2018 Abstract Background. Recent epidemiological studies have provided evidence that myotonic dystrophy type I (DM1) patients are at excess risk of cancer, but inconsistencies in reported cancer sites exist. The risk of benign tumors and contributing factors to tu... Keywords Cancer; Tumors; Cataract; Comorbidity; Diabetes Mellitus; Myotonic Dystrophy; Neoplasms; Thyroid Diseases Download date 07/10/2021 07:06:48 Link to Item http://hdl.handle.net/10713/7926 Rotana Alsaggaf, M.S. Pre-doctoral Fellow - Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH PhD Candidate – Department of Epidemiology & Public Health, University of Maryland, Baltimore Contact Information Business Address 9609 Medical Center Drive, 6E530 Rockville, MD 20850 Business Phone 240-276-6402 Emails [email protected] [email protected] Education University of Maryland – Baltimore, Baltimore, MD Ongoing Ph.D. Epidemiology Expected graduation: May 2018 2015 M.S. Epidemiology & Preventive Medicine Concentration: Human Genetics 2014 GradCert. Research Ethics Colorado State University, Fort Collins, CO 2009 B.S. Biological Science Minor: Biomedical Sciences 2009 Cert. Biomedical Engineering Interdisciplinary studies program Professional Experience Research Experience 2016 – present Pre-doctoral Fellow National Cancer Institute, National Institutes
    [Show full text]
  • 346 Fetal Cardiac Rhabdomyoma: a Case Report
    A CASE REPORT Bali Medical Journal (Bali Med J) 2016, Volume 5, Number 3: 543-546 P-ISSN.2089-1180, E-ISSN.2302-2914 Fetal cardiac rhabdomyoma: a case report A Case Report Tjokorda Gde Agung Suwardewa,1* I Ketut Surya Negara,1 AAN Jaya Kusuma,1 AAP Wiradnyana,1 Ryan Mulyana Surya,1 I Ketut Tunas2 CrossMark Doi: http://dx.doi.org/10.15562/bmj.v5i3.346 Published by DiscoverSys ABSTRACT Volume No.: 5 Background: Fetal cardiac rhabdomyoma is a rare condition. tomography scan, to rule out anything related to tuberous sclerosis. Case: We report a case with cardiac mass discovered in utero by The prognosis depends on the size, site, number of tumors, and co- prenatal ultrasonography at 33 weeks of gestational age. An echogenic existing congenital abnormalities. Management highly depends on Issue: 3 round-oval shape mass at the interventricular septum protrudes to left the presence of outflow tract obstruction of the heart. However, some ventricle was observed. cases may regress after birth. Results: After birth, the baby was followed up for 7 months with echocardiography, physical examination, and computerized First page No.: 543 Keywords: rhabdomyoma, fetal heart, tuberous sclerosis. Cite This Article: Suwardewa, T., Surya Negara, I., Jaya Kusuma, A., Wiradnyana, A., Surya, R., Tunas, I. 2016. Fetal cardiac rhabdomyoma: a case P-ISSN.2089-1180 report. Bali Medical Journal 5(3): 543-546. DOI:10.15562/bmj.v5i3.346 1Department of Obstetrics and INTRODUCTION rhabdomyoma, which found incidentally during a E-ISSN.2302-2914 Gynecology, Udayana University / routine antenatal visit. Sanglah Hospital Denpasar, Bali- The presence of a primary congenital tumor of Indonesia.
    [Show full text]
  • Statistical Analysis Plan
    Cover Page for Statistical Analysis Plan Sponsor name: Novo Nordisk A/S NCT number NCT03061214 Sponsor trial ID: NN9535-4114 Official title of study: SUSTAINTM CHINA - Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Document date: 22 August 2019 Semaglutide s.c (Ozempic®) Date: 22 August 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.9 16.1.9 Documentation of statistical methods List of contents Statistical analysis plan...................................................................................................................... /LQN Statistical documentation................................................................................................................... /LQN Redacted VWDWLVWLFDODQDO\VLVSODQ Includes redaction of personal identifiable information only. Statistical Analysis Plan Date: 28 May 2019 Novo Nordisk Trial ID: NN9535-4114 Version: 1.0 CONFIDENTIAL UTN:U1111-1149-0432 Status: Final EudraCT No.:NA Page: 1 of 30 Statistical Analysis Plan Trial ID: NN9535-4114 Efficacy and safety of semaglutide once-weekly versus sitagliptin once-daily as add-on to metformin in subjects with type 2 diabetes Author Biostatistics Semaglutide s.c. This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.This
    [Show full text]